Royal Bank of Canada’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-25
Closed 7205
2018
Q2
$0 Hold
25
﹤0.01% 6994
2018
Q1
$0 Sell
25
-626
-96% -$5.26K ﹤0.01% 7157
2017
Q4
$3K Sell
651
-6,250
-91% -$30.4K ﹤0.01% 6238
2017
Q3
$31K Buy
6,901
+26
+0.4% +$122 ﹤0.01% 5717
2017
Q2
$35K Sell
6,875
-37
-0.5% -$166 ﹤0.01% 5298
2017
Q1
$33K Buy
6,912
+37
+0.5% +$187 ﹤0.01% 5380
2016
Q4
$39K Hold
6,875
﹤0.01% 5414
2016
Q3
$38K Sell
6,875
-90
-1% -$595 ﹤0.01% 5285
2016
Q2
$49K Hold
6,965
﹤0.01% 5140
2016
Q1
$46K Sell
6,965
-4,000
-36% -$29.4K ﹤0.01% 5169
2015
Q4
$113K Sell
10,965
-55
-0.5% -$638 ﹤0.01% 4872
2015
Q3
$130K Hold
11,020
﹤0.01% 4608
2015
Q2
$101K Buy
11,020
+55
+0.5% +$415 ﹤0.01% 4829
2015
Q1
$68K Sell
10,965
-62,664
-85% -$388K ﹤0.01% 4821
2014
Q4
$412K Buy
73,629
+66,670
+958% +$388K ﹤0.01% 3770
2014
Q3
$41K Sell
6,959
-97
-1% -$592 ﹤0.01% 5039
2014
Q2
$49K Buy
7,056
+83
+1% +$555 ﹤0.01% 4854
2014
Q1
$50K Buy
6,973
+14
+0.2% +$97 ﹤0.01% 4868
2013
Q4
$46K Buy
6,959
+3
+0% +$20 ﹤0.01% 4935
2013
Q3
$51K Buy
+6,956
New +$46.8K ﹤0.01% 4811

Royal Bank of Canada's JNP Position: Q3 2018 in Review

Royal Bank of Canada sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 25 shares.

Royal Bank of Canada first reported a position in JNP in Q3 2013 and held it in 20 quarters. The position peaked at $412K in Q4 2014. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.

  • Royal Bank of Canada reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Royal Bank of Canada sold 25 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018.
  • Royal Bank of Canada first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 20 quarters.
  • Royal Bank of Canada's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $412K in Q4 2014.
  • 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on Royal Bank of Canada's 13F filing for Q3 2018, filed 14 Nov 2018.